ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
13 hedge funds and large institutions have $1.4M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0.26% less ownership
Funds ownership: 10.36% → 10.1% (-0.26%)
19% less funds holding
Funds holding: 16 → 13 (-3)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
39% less capital invested
Capital invested by funds: $2.29M → $1.4M (-$885K)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$304K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$144K |
| 3 |
Morgan Stanley
New York
|
+$15.7K |
| 4 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$4.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$411K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$271K |
| 3 |
Jane Street
New York
|
-$191K |
| 4 |
PFS
Prospera Financial Services
Dallas,
Texas
|
-$166K |
| 5 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$28.5K |
CNCR Hedge Fund Activity: Q2 2024 in Review
13 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q2 2024, worth a combined $1.4M — down 39% from $2.29M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CNCR and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $304K. The largest seller was Citadel Advisors, exiting entirely with an estimated $411K sold.
- 13 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q2 2024, down from 16 in Q1 2024.
- Funds reported $1.4M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q2 2024, down 39% quarter-over-quarter.
- 2 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q2 2024 and 5 closed out, a net change of -3 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q2 2024 was Susquehanna International Group, an estimated $304K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q2 2024 was Citadel Advisors, an estimated $411K sold.
Based on aggregated 13F filings for Q2 2024.